Claims for Patent: 9,757,548

Summary for Patent: 9,757,548

Title:	Method for delivering a therapeutic agent into the wall of the small intestine
Abstract:	Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Inventor(s):	Imran; Mir A. (Los Altos Hills, CA)
Assignee:	Rani Therapeutics, LLC (San Jose, CA)
Application Number:	14/282,864
Patent Claims:	1. A method for delivering a therapeutic agent into the wall of the small intestine, the method comprising: swallowing a drug delivery device comprising a capsule, an actuator having a first configuration and a second configuration and a therapeutic preparation operably coupled to the actuator, the therapeutic preparation comprising a therapeutically effective dose of at least one therapeutic agent, the preparation being contained within the capsule in the first configuration and advanced out of the capsule and into the small intestine wall in the second configuration so as to deliver the therapeutic agent into the lumen wall, the preparation supplied in the capsule in a shaped form which can be directly delivered from inside the capsule into the wall of the small intestine by the application of force on a surface of the preparation; and actuating the actuator responsive to a condition in the small intestine to directly deliver the therapeutic agent from the capsule into the wall of the small intestine. 2. The method of claim 1, wherein the condition is a selected pH. 3. The method of claim 2, wherein the pH is above about 7.1. 4. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of insulin for the treatment of diabetes or a glucose regulation disorder. 5. The method of claim 4, further comprising: using the dose of delivered insulin to control a blood glucose level of a patient without injecting insulin into the patient. 6. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of an incretin for the treatment of diabetes or a glucose regulation disorder. 7. The method of claim 6, further comprising: using the dose of delivered incretin to control a blood glucose level of a patient without injecting incretin into the patient. 8. The method of claim 6, wherein the incretin comprises a glucagon like peptide-1 (GLP-1), a GLP-1 analogue, exenatide, liraglutide, albiglutide, taspoglutide or a gastric inhibitory polypeptide (GIP). 9. The method of claim 6, wherein the incretin comprises exanatide and the dose is in a range from about 1 to 10 .mu.g. 10. The method of claim 1, wherein the therapeutic agent comprises a combination of therapeutic agents for the treatment of diabetes or a glucose regulation disorder. 11. The method of claim 10, further comprising: using the dose of delivered therapeutic agents to control a blood glucose level of a patient without injecting incretin into the patient. 12. The method of claim 11, wherein the combination comprises exenatide and metformin. 13. The method of claim 12, wherein the dosages of the exenatide and the metformin are matched to produce an improved level of blood glucose control for an extended period. 14. The method of claim 13, wherein the extended period is up to about a day. 15. The method of claim 13, wherein the extended period is up to about a week. 16. The method of claim 12, wherein the dose of exenatide is in a range of about 1 to 10 .mu.g and the dose of metformin is in a range of about 1 to 3 grams. 17. The method of claim 10, wherein the combination comprises a therapeutically effective dose of an incretin and a therapeutically effective dose of a biguanide. 18. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of growth hormone. 19. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of parathyroid hormone for the treatment of osteoporosis or a thyroid disorder. 20. The method of claim 19, further comprising: using the dose of delivered parathyroid hormone to treat the osteoporosis or a thyroid disorder without injecting parathyroid hormone into the patient. 21. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of a chemotherapeutic agent for the treatment of cancer. 22. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of an antibiotic. 23. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of an antiviral compound. 24. The method of claim 1, further comprising: delivering a first and a second therapeutic agent.

Details for Patent 9,757,548

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014		2029-12-24
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2029-12-24